Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration advisory panel next month, a move that suggests a more stable approach to drug reviews after the firing of former agency head Marty Makary. The panel will meet on June 18 to discuss and make recommendations on the safety and effectiveness of Moderna’s MFLUSIVA flu vaccine, according to a Federal Register notice published…